Trial Profile
A Phase 1, Open-label, Single-centre Study Investigating the Effect of C21 on Forearm Blood Flow in Healthy Male Subjects by Use of Strain-gauge Venous Occlusion Plethysmography
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 15 Nov 2022
Price :
$35
*
At a glance
- Drugs C-21 (Primary) ; Sodium nitroprusside
- Indications Idiopathic pulmonary fibrosis
- Focus Therapeutic Use
- Sponsors Vicore Pharma
- 11 Nov 2022 Status changed from active, no longer recruiting to completed.
- 21 Sep 2022 Primary endpoint (Change from baseline in forearm blood flow in response to increasing intraarterial doses of C21) has been met, according to a Vicore Pharma media release.
- 21 Sep 2022 Results published in the Vicore Pharma Media Release.